Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Takes Sides in the Statin Wars

This article was originally published in RPM Report

Executive Summary

The Centers for Medicare & Medicaid Services is showing a lot more interest in ensuring broad access to low-cost generic drugs now that the agency is overseeing the implementation of Medicare Part D. As evidence of this trend, CMS considered weighing in on a court decision regarding the availability of Zocoor generics.

You may also be interested in...



CMS Administrator Berwick Visits the Hill

Medicare Part D and prescription drug prices come up briefly in a brief appearance by controversial CMS head Berwick before the Senate Finance Committee.

Building the Right Foundation: An Interview with Mark McClellan

The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.

Clinical Update (02/2007)

A brief summary of recent clinical developments impacting the medical device industry, including limb regeneration, NIH's research plan for Type I diabetes, heart failure and statins; and new glaucoma research.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel